UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

Antimicrobial Agents and Chemotherapy, 2003-01, Vol.47 (1), p.350-359

2003

Volltextzugriff (PDF)

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

Nature medicine, 1996-07, Vol.2 (7), p.760-766

1996

Volltextzugriff (PDF)

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

Clinical pharmacokinetics, 1997-03, Vol.32 (3), p.210-258

1997

Volltextzugriff (PDF)

Ritonavir : Clinical pharmacokinetics and interactions with other anti-HIV agents

Clinical pharmacokinetics, 1998-10, Vol.35 (4), p.275-291

1998

Volltextzugriff (PDF)

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

Clinical therapeutics, 2003-06, Vol.25 (6), p.1700-1721

2003

Volltextzugriff (PDF)

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Antimicrobial Agents and Chemotherapy, 1998-12, Vol.42 (12), p.3218-3224

1998

Volltextzugriff (PDF)

Once-a-Day Extended-Release Dosage form of Divalproex Sodium III: Development and Validation of a Level A in Vitro–in Vivo Correlation (IVIVC)

Journal of pharmaceutical sciences, 2005-09, Vol.94 (9), p.1949-1956

2005

Volltextzugriff (PDF)

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

Drug metabolism and disposition, 1999-08, Vol.27 (8), p.902

1999

Volltextzugriff (PDF)

Are Bioequivalence Studies of Levothyroxine Sodium Formulations in Euthyroid Volunteers Reliable?

Thyroid (New York, N.Y.), 2004-03, Vol.14 (3), p.191-200

2004

Volltextzugriff (PDF)

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

Clinical pharmacology and therapeutics, 1998-04, Vol.63 (4), p.453-464

1998

Volltextzugriff (PDF)

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

British journal of clinical pharmacology, 1998-08, Vol.46 (2), p.111-116

1998

Volltextzugriff (PDF)

Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy

Epilepsy research, 2003-02, Vol.53 (1), p.19-27

2003

Volltextzugriff (PDF)

Recent developments in HIV protease inhibitor therapy

Antiviral Research, 1998-07, Vol.39 (1), p.1-23

1998

Volltextzugriff (PDF)

Pharmacokinetic interaction between ritonavir and clarithromycin

Clinical pharmacology and therapeutics, 1998-10, Vol.64 (4), p.355-362

1998

Volltextzugriff (PDF)

Every-12-hour administration of extended-release divalproex in patients with epilepsy: Impact on plasma valproic acid concentrations

Epilepsy & behavior, 2006-03, Vol.8 (2), p.391-396

2006

Volltextzugriff (PDF)

Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation

Epilepsy research, 2003-02, Vol.53 (1), p.29-38

2003

Volltextzugriff (PDF)

A Phase I Multiple-Dose Escalation Study Characterizing Pharmacokinetics and Safety of ABT-578 in Healthy Subjects

Journal of clinical pharmacology, 2005-08, Vol.45 (8), p.910-918

2005

Volltextzugriff (PDF)

Effect of Fluoxetine on Pharmacokinetics of Ritonavir

Antimicrobial Agents and Chemotherapy, 1998-12, Vol.42 (12), p.3107-3112

1998

Volltextzugriff (PDF)

Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2‐receptor antagonist AA‐2414 in normal subjects: Population analysis

Clinical pharmacology and therapeutics, 1994-04, Vol.55 (4), p.441-450

1994

Volltextzugriff (PDF)

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects

Clinical pharmacology and therapeutics, 1997-08, Vol.62 (2), p.157-164

1997

Volltextzugriff (PDF)

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety

International clinical psychopharmacology, 1997-02, Vol.12 Suppl 1, p.S29-S36

1997

Volltextzugriff (PDF)

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics

Clinical pharmacology and therapeutics, 1996-07, Vol.60 (1), p.48-53

1996

Volltextzugriff (PDF)

Simultaneous Modeling of the Pharmacokinetic and Pharmacodynamic Properties of Enalkiren (Abbott-64662, A Renin Inhibitor). II: A Dose-Ranging Study in Patients with Congestive Heart Failure

Journal of cardiovascular pharmacology, 1993-05, Vol.21 (5), p.834-840

1993

Volltextzugriff (PDF)

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium

The journal of clinical psychiatry, 1996-05, Vol.57 (5), p.204

1996

Volltextzugriff (PDF)

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Antimicrobial Agents and Chemotherapy, 1997-03, Vol.41 (3), p.654-660

1997

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(75)

Sprache

Englisch
(75)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Humans
(63)
Male
(51)
Science & Technology
(51)
Adult
(48)
Life Sciences & Biomedicine
(47)
Biological And Medical Sciences
(38)
Medical Sciences
(38)
Pharmacology. Drug Treatments
(38)
Pharmacology & Pharmacy
(37)
Drug Interactions
(25)
Female
(23)
Middle Aged
(23)
Administration, Oral
(22)
Double-Blind Method
(18)
Area Under Curve
(17)
Chromatography, High Pressure Liquid
(16)
Cross-Over Studies
(16)
Dose-Response Relationship, Drug
(15)
Neuropharmacology
(14)
Half-Life
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

Ritonavir : Clinical pharmacokinetics and interactions with other anti-HIV agents

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Once-a-Day Extended-Release Dosage form of Divalproex Sodium III: Development and Validation of a Level A in Vitro–in Vivo Correlation (IVIVC)

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

Are Bioequivalence Studies of Levothyroxine Sodium Formulations in Euthyroid Volunteers Reliable?

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy

Recent developments in HIV protease inhibitor therapy

Pharmacokinetic interaction between ritonavir and clarithromycin

Every-12-hour administration of extended-release divalproex in patients with epilepsy: Impact on plasma valproic acid concentrations

Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation

A Phase I Multiple-Dose Escalation Study Characterizing Pharmacokinetics and Safety of ABT-578 in Healthy Subjects

Effect of Fluoxetine on Pharmacokinetics of Ritonavir

Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2‐receptor antagonist AA‐2414 in normal subjects: Population analysis

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics

Simultaneous Modeling of the Pharmacokinetic and Pharmacodynamic Properties of Enalkiren (Abbott-64662, A Renin Inhibitor). II: A Dose-Ranging Study in Patients with Congestive Heart Failure

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Suchergebnisse filtern